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Advances in the therapy of 
cancer pain: 
from novel experimental 
models to evidence-based 
treatments
ABSTRACT
Cancer related pain may be due to the malignant disease itself, or subsequent to treatments, such as surgery, chemotherapy 
or radiation therapy. The pathophysiology of pain due to cancer may be complex and include a variety of nociceptive, 
inflammatory, and neuropathic mechanisms.  Despite modern advances in pharmacotherapy, cancer pain remains overall 
under-treated in a world-wide scale, and a main reason is lack of understanding of its pertinent pathophysiology and basic 
pharmacology. 
Recently, pertinent animal models have facilitated understanding of the pathobiology and have advanced the pharmacology 
of cancer pain, with significant translational applicability to clinical practice. Furthermore, quantitative and qualitative 
systematic reviews, integrating the best available evidence, indicate the validity of treatments that fit into an expanded 
view of the WHO-analgesic ladder. Appropriate current treatments include a valid therapeutic role of non-opioid and 
opioid analgesics, adjuvants -such as gabapentin, biphosphonates, palliative radiation therapy and radiopharmaceutical 
compounds, and interventional pain therapy (including neuraxial drug infusion and verterbroplasty for spine metastases) 
in selected patients. 
Overall, experimental animal models simulating cancer pain have been useful in providing pertinent information on the 
pathophysiology of cancer pain, and provide a testing ground for established and novel therapies, which are validated by 
clinical evidence. This is clinically significant, considering the epidemiological dimensions and the problematic nature of 
cancer pain.
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The epidemiology of cancer 
pain today
Despite several recent advances in 
the management of pain and pallia-
tive care, intractable pain from cancer 
remains a significant epidemiological, 
clinical and social/financial burden in 
the world today. Judging from the data 
reported by the World Health Organiza-
tion (WHO) (World Health Organization 
(WHO) Cancer Control Programme. 
Available online at <http://www.who.
int./cancer>), on a world-wide scale 
more than 11 million people are diag-
nosed with cancer every year.  So, it 
is estimated that there will be 16 mil-
lion new cases of cancer every year 
by 2020. Cancer-related morbidity is 
7 million deaths per year (1), but, as a 
result of advances in cancer therapy 
most cancer patients survive longer 
now. Nevertheless, prolonged survival 
is associated with a parallel increased 
prevalence of pain, one of the main 
manifestations of cancer and its con-
sequences. In a category of patients, 
also, cancer disease may have been 
successfully cured, but the chronic pain 
disease may still persist.
Even in countries with advanced health 
care systems, the current prevalence 
of persisting pain in cancer patients 
remains overall high (52%) (2). The 
prevalence of pain in patients with 
advanced disease, such as in patients 
with metastases to the bones, has 
been even higher, reaching 61%. Can-
cer pain is particularly troublesome 
regarding its intensity and impact on 
quality of life in the presence of metas-
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tases to the bones, emergence of fre-
quent episodes of breakthrough pain, 
and abnormal cutaneous sensitivity, 
including allodynia and hyperalgesia. 
Paradoxically, even patients who were 
receiving therapy with opioids (42%) 
reported persisting pain, which was 
actually of higher intensity than the pain 
in those who were not on opioids. These 
patients, despite being on opioids, suf-
fered also from more frequent break-
through pain, and demonstrated higher 
impairment of daily activities and quality 
of life. Finally, a significant percentage 
(30%) of patients suffering from severe 
pain were not receiving opioids or any 
analgesics at all. 
In a more wide scale, it has been esti-
mated that the mean prevalence of can-
cer pain ranges between 20 and 100% 
in the general adult population, with 
higher values amongst those suffering 
from advanced cancer (3). In certain 
countries treatment of cancer pain is 
even more inadequate, and this has 
been attributed to under-utilization or not 
proper use of analgesic treatments by 
physicians which constitutes a problem 
of an even greater magnitude (4-7). 
Certain subgroups of cancer patients 
seem to suffer more than others from 
pain. Meuser et al have confirmed that 
the prevalence and intensity of cancer-
related pain is much higher amongst 
those patients with metastatic disease 
or advanced stages of cancer. The 
prevalence of pain amongst those with 
advanced, metastatic cancer reaches 
95%, and its intensity ranges between 
7-8 in a VRS 1-10 scale, also despite the 
fact that 92% of these patients receive 
opioids and 42% adjuvant analgesics. 
These findings have been attributed 
to inappropriate doses prescribed, 
or administration from inappropriate 
routes, apparently due to insufficient 
education of physicians and other health 
care professionals, or even due to fear 
of undesirable side effects (8, 9). 
Overall, lack or failure of treatment to 
control cancer pain has been attributed 
mainly to lack of appropriate knowledge 
or ineffective individual assessment for 
pertinent symptoms, resulting in under-
utilization or improper use of analgesic 
resources. Lack of understanding of 
the specific pathophysiology of pain 
induced by cancer, and particularly 
by metastatic cancer to the bones, is 
a major obstacle. Most current treat-
ments have been established as a 
result of accumulating clinical experi-
ence or as a consequence of clinical 
studies only.
Nevertheless, pertinent animal models 
recently have significantly contributed 
to relevant knowledge, the translation of 
which to clinical practice, may improve 
cancer pain treatment by guiding 
appropriate, effective therapies. 
The pathophysiology of 
cancer pain
The causative etiology of cancer is usu-
ally complex and multi-factorial. The dis-
ease of cancer itself may cause pain 
as a result of direct tumor expansion, 
progressing to invasion and damage 
to nearby tissues, and /or as a result of 
nerve infiltration causing neuropathic 
pain, or due to paraneoplastic syn-
dromes. However, all of the treatment 
modalities used to treat cancer have 
the capacity to cause pain, too. This 
is the case with chemotherapy, radia-
tion therapy and surgical procedures. 
Spe-cifically, chemotherapeutic agents, 
such as platinum compounds (cisplatin, 
oxaliplatin or carboplatin) may produce 
pure painful sensory neuropathies, while 
others such as vincristine, or suramin 
may induce mixed sensorimotor neu-
ropathies, with or without autonomic 
involvement (10). The same is the case 
with paclitaxel or docetaxel, promot-
ers of the polymerization of tubulin that 
leads to mitotic cell arrest, which are del-
eterious to neurons and glia, and result 
in cumulative, predominantly sensory, 
painful peripheral neuropathy (11). The 
overall incidence of neuropathic pain 
after chemotherapy is high (30-70%) 
(12). Radiation therapy may also induce 
injury, leading to microvascular insuf-
ficiency and fibrotic changes affecting 
the nerves and perineural tissues (13), 
with clinical painful manifestations rang-
ing between 25 and 47% (14). Finally, 
surgery for diagnostic or therapeutic 
purposes, may lead to chronic pain as 
well, with incidence reaching high rates 
(60-90%) in some cases, such as after 
surgery for breast cancer (15-18). Post-
mastectomy pain syndrome may be 
particularly troublesome and adversely 
impair the quality of life of female breast 
cancer survivors. It is also likely that cer-
tain individuals with cancer suffer from 
multiple painful syndromes, of varying 
etiology and underlying mechanisms. 
Other conditions, separate from can-
cer, may also produce pain in cancer 
patients, such coexisting painful condi-
tions, infections (herpes zoster), etc.
Nevertheless, pain in patients with can-
cer most commonly occurs from pres-
sure, infiltration or tumor invasion into 
structures with high sensitivity sensitive 
to noxious stimulation, such as bones, 
nerves, viscera, pleura, blood vessels 
and other soft tissues. Pain from meta-
static tumors damaging bones, pain 
from nerve compression from tumor 
growth, from involvement of pleural 
membranes, distention of capsular 
organs, and other mechanisms is very 
common. In terms of specific patho-
physiology, the cancer pain may be 
mechanistically classified as “nocicep-
tive” or “neuropathic”. 
Nociceptive pain originates as a result 
of tissue damage or inflammation of 
somatic or visceral tissues, wherein 
mechanical, chemical or thermal noxious 
stimuli activate peripheral nociceptive 
nerve terminals. These nerve endings 
transduce noxious stimulation into elec-
trical and synaptic signaling, that sub-
sequently conveys nociceptive signals 
to the dorsal horns of the spinal cord. In 
neuropathic pain, nerve injury or various 
alterations originating from the disease 
or attempts to treat it therapeutically, 
result in increased excitability at the sites 
of the injury and the peripheral sensory 
neuronal somata in the dorsal root gan-
glia (DRG). Subsequent aberrant elec-
trical signaling ends up in enhanced 
synaptic transmission and activation 
of postsynaptic neurons in the spinal 
cord. Other mechanisms may partici-
pate in the pathogenesis of pain in the 
latter case, such as enhanced neuronal 
cell death, activation of sympathetic 
mechanisms, or dynamic reorganization 
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of the synaptic network at the dorsal 
horns (19, 20). 
Prolonged, intense nociception originat-
ing from tissue damage (such as after 
bone destruction from metastases) or 
inflammation (such as from mechanical 
or chemical activation of nociceptors by 
tumor), may produce sensitization at 
peripheral (and subsequently at central) 
afferent sensory pathways, enhancing 
their responsiveness to incoming stimu-
li. A variety of transmitters are known to 
mediate the development of sensitiza-
tion or excitation of peripheral sensory 
neurons. These transmitters include pro-
tons and potassium ions, adenosine tri-
phosphate (ATP), bradykinin, serotonin, 
prostaglandins, and leukotrienes. Ele-
vated afferent traffic of nociceptive sig-
naling from peripheral tissues, or aber-
rant ongoing firing of injured peripheral 
sensory neurons results in enhanced 
synaptic transmission (via increased 
release of excitatory aminoacids -such 
as glutamate, and neurokinins -such as 
substance P), leading to enhanced post-
synaptic responses at dorsal horn neu-
rons. Thus the latter also get sensitized 
to incoming stimuli. Central sensitization 
may even result in spontaneous firing 
of postsynaptic neurons at the dorsal 
horns, even in the absence of incoming 
stimuli from the periphery. The activation 
of the NMDA receptor, with aberrant cal-
cium influx and up-regulation of complex 
intracellular signaling cascades, leading 
to altered gene expression and altered 
post-translational modification, is pivotal 
in the mediation of central sensitization. 
Central sensitization results in manifes-
tations, such secondary hyperalgesia 
in tissues beyond the area of the injury, 
allodynia, and enhanced, persistent pain 
states. Painful nerve injury (like after inva-
sion of neural plexuses by tumor, or after 
injury by surgery, chemotherapy or radia-
tion therapy) in particular, is exception-
ally capable of inducing sensitization at 
peripheral and central nerve pathways. 
Peripheral and central neurons respond 
with spontaneous, ectopic firing, and 
the resultant signaling results in aberrant 
plasticity involving the central nervous 
system, possibly at all levels. Subse-
quent clinical manifestations include 
unpleasant pain sensations (burning 
and shooting or lancinating pain) allo-
dynia and hyperalgesia, combined with 
sensory changes, including dysesthe-
sia or loss of normal sensation in painful 
areas. 
The mouse bone cancer 
pain model
Pain from cancer metastasizing to the 
bones is manifested as dull and achy in 
quality, initially episodic and of moderate 
intensity, but progressively getting more 
frequent and more intense. Bone can-
cer pain eventually becomes constant, 
severe, and particularly disabling. Bone 
cancer pain usually has a constant, 
ongoing component, which may be 
interrupted by episodes of breakthrough 
pain, which may not, or may be related 
to certain activities, such as turning in 
bed, sitting, standing, or walking.  
Metastases to the bones are a very 
common cause of pain amongst cancer 
patients. The majority of cancer patients 
with metastases to the bones will experi-
ence severe pain. In addition to pain, 
disability, lack of independence and 
limited mobility may be equally debili-
tating problems in these patients, and 
significantly impair their quality of life. 
Collapse from tumors metastasizing 
to the vertebrae of the spine may also 
produce significant neurological com-
promise, even paraplegia and/or bowel 
and bladder incontinence, by compres-
sion to the spinal cord and/or the spinal 
nerve roots.
Metastases to the bones occur when-
ever tumor cells, transferred usually 
via the blood flow, attach to bone mar-
row and matrix, wherein reside and 
uncontrollably proliferate. This aberrant 
cellular growth results in stimulation 
of osteoclasts, producing osteolytic 
damage to the bone, and osteoblasts, 
producing new bone formation. These 
opposing processes occur in varying 
combinations, depending on the type 
of the tumor, but, overall by altering the 
normal bone remodeling, they result 
in damage of varying degree. This is 
clinically manifested with pathological 
fractures, pain, neurological impair-
ment, and hypercalcemia. 
Treatment is mainly based on analge-
sic medications, such as opioids and 
NSAID medications administered alone 
or in combinations, but effective pain 
control may be limited by the devel-
opment of side effects in high doses. 
Other treatment options may be help-
ful, such as radiation therapy or inter-
ventional techniques, but even these 
are not without significant drawbacks. 
One of the main reasons for lack of 
specific, efficacious treatments is the 
lack of clear understanding of the basic 
pathophysiology involved in the genesis 
of pain from metastases to the bones, 
and its relevant pharmacology. 
Animal models of pain have so far 
facilitated understanding of mecha-
nisms of several types of pain, such 
as neuropathic (21, 22)  or acute post-
operative pain (23).  Several of these 
animal models have been shown to be 
highly predictive of the pathobiology 
and pharmacology pertinent to human 
pain states (24). 
Until recently no specific animal model 
existed with regard to simulating the 
basic pathogenetic mechanisms of 
cancer pain. The latter remained essen-
tially unknown, and reflected to treat-
ments that were mainly empirically driv-
en rather than based on understand-
ing of the mechanisms and pertinent 
pharmacology. Most therapies were 
guided by available clinical observa-
tions and studies. Available informa-
tion from pertinent experimental studies 
was minimal. Regarding pathophysiol-
ogy and mechanisms of pain produced 
by cancer, a known fact was that there 
is minimal direct innervation of tumors 
(25), while tumor cells may produce 
sensitization and/or direct excitation 
of primary afferent neurons by release 
of pro-nociceptive mediators, such as 
prostaglandins, cytokines and various 
growth factors (26-28).
In an attempt to understand the patho-
physiology of cancer pain in a man-
ner that would produce new pertinent 
knowledge leading to novel therapies 
for pain, Schwei and Mantyh developed 
a pertinent mouse model of bone can-
cer pain, in order to elucidate specific 
mechanisms that produce pain after 
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metastases to the bones (29). This has 
been proven to be a very successful 
animal model and reliably simulates 
several features of the cancer-induced 
bone pain in humans (30). In this model, 
osteolytic sarcoma cells are injected 
directly into the intramedullary (bone 
marrow) space of the femoral bone, 
and retained within this space by an 
amalgam plug in the site of the injec-
tion, which is sealing the needle hole. 
Thus, the tumor cells are contained and 
start proliferating within the intramedul-
lary space, developing changes that 
characterize a metastatic bone lesion. 
As the experimental metastatic tumor 
grows within the femoral bone, sub-
sequent to the bone destruction and 
stimulation of nociceptive pathways, 
the following manifestations develop 
that can be measured or objectively 
documented as specific and objective 
end-points: 
1. Radiographic findings indicative of 
bone destruction. In parallel to tumor 
growth there is radiographic evidence 
of progressive loss of mineralized bone. 
This bone destruction increases as the 
time goes by from the time of the injec-
tion.  Approximately one week after the 
sarcoma cell injection there is histologi-
cal evidence of bone destruction, which 
becomes radiologically evident by 10 
days to two weeks. Usually by the third 
week post-injection there is complete 
demineralization and extensive damage 
of the underlying bone, with pathologi-
cal fractures frequently evident (31). At 
about the same time (2-3 weeks) tumor 
cells break through the bone expanding 
into the nearby soft tissues, producing 
a swelling of the extremity size. 
2. Quantifiable tumor growth. Trans-
fection of the tumor cells with a fluo-
rescent marker allows observation and 
quantification of the tumor growth and 
migration within the bone. It has been 
thus shown that usually within one week 
labeled tumor cells are localized nearby 
the injection site, while after approxi-
mately two weeks they have proliferated 
and occupied the entire intramedullary 
space within the femoral bone. Later 
on, these tumor cells break through 
the bone into the limb soft tissues (2-3 
weeks after cell inoculation), produc-
ing a macroscopic increase of the limb 
size from the fourth week (32). Radio-
logic, histopathologic and macroscopic 
expansion of the tumor correlates well 
with behavioral manifestations of pain. 
3. Manifestations of spontaneous and 
evoked pain. Radiographic findings 
of bone destruction, as well as tumor 
growth, are paralleled by reproducible 
and measurable behavioral manifesta-
tions of pain. These are proportional 
to the extent of the tumor growth and 
bone damage, and include flinching 
and guarding of the paw, that can be 
spontaneous, or evoked by palpation. 
Thus these manifestations simulate 
the mechanically induced episodes of 
breakthrough pain in humans. All these 
behavioral manifestations of pain devel-
op in parallel and correlate well with the 
progression of bone damage and the 
expansion of tumor into the soft tissues 
(33). There is also initially decreased 
responsiveness to thermal stimuli (ther-
mal hypoalgesia). With the expansion of 
the tumor, however, thermal hypoalge-
sia is replaced by thermal hyperalgesia 
(increased responsiveness to noxious 
heat) after the fourth week, while initial 
manifestations of spontaneous pain 
and mechanical hyperalgesia intensify 
reaching a peak 3 weeks post-injection. 
The initial paradoxical thermal hypoalge-
sia has been attributed to activation of 
endogenous opioid mechanisms (32). 
These mediate descending analge-
sic systems or inhibitory circuits in the 
dorsal horns. Activated endogenous 
opioid mechanisms may explain the 
fact that some patients may remain free 
of any painful manifestations of meta-
static bone cancer until the later stages 
of the disease. The subsequent devel-
opment of thermal hyperalgesia may be 
secondary to release of pro-nociceptive 
substances by the tumor cells, such as 
endothelin-1, a mediator able to induce 
thermal hyperalgesia (34). Furthermore 
tumor development has been shown 
to induce development of spontane-
ous electrical activity and sensitization 
of C-fibers which provide innervation 
in and around the affected bone (35). 
The role of endogenous opioid-ergic 
analgesia systems has been also dem-
onstrated by Mantyh’s group, in anoth-
er animal cancer pain model, wherein 
genetically modified transgenic mice 
under control of a promoter, spontane-
ously develop pancreatic cancer. Only 
mice with advanced pancreatic cancer, 
but not those in early stages, display 
spontaneous, morphine-reversible vis-
ceral pain behaviors. However, rats 
with early stage cancer exhibit signifi-
cant pain behaviors too, after adminis-
tration of opioid receptor antagonists 
(naloxone or naltrexone). These find-
ings indicate that endogenous CNS 
opioid-dependent mechanisms toni-
cally modulate pancreatic cancer pain 
at early and late stages, and may mask 
cancer pain in early stages (36). It is 
likely that in several types of cancer, 
the slow and gradual development of 
tumor growth provides a persistent, 
ongoing low-grade nociceptive input to 
the CNS that induces the activation of 
endogenous modulatory circuits. These 
suppress initial pain, but are overridden 
at later, more advanced stages of can-
cer, leading to the eventual perception 
of cancer pain. 
The specificity of this experimental 
model of metastatic bone cancer pain, 
induced by cancer tumors metastasiz-
ing to the bones, as well as its capacity 
to simulate the underlying pathophysi-
ological mechanisms, is indicated by 
the following observations:
1. Structural and functional reorganiza-
tion of the dorsal horns of the spinal 
cord as a result of incoming pain sig-
naling is a well-known manifestation 
of chronic pain states. However, the 
reorganization pattern observed in the 
mouse model of metastatic bone pain 
is specific, and distinctly different than 
the patterns observed after chronic 
inflammatory or neuropathic pain. In 
addition, these alterations correlate well 
with the extent of bone destruction as a 
result of the tumor growth. Specifically, 
in this model, afferent traffic of signals 
of pain induce a significant, distinct 
pattern of neuroplasticity with reorgani-
zation of the spinal cord segments that 
receive these signals. Ipsilateral to the 
affected bone in the spinal cord, a mas-
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sive astrocyte hypertrophy develops, as 
evident by a profound increase in glial 
fibrillary acidic protein (GFAP) staining, 
without neuronal loss. There is also an 
ipsilateral up-regulation in the expres-
sion of the pro-hyperalgesic peptide 
dynorphin and c-fos protein in neurons 
in the deep laminae of the dorsal horn. 
Additionally, normally innocuous pal-
pation of the limb with cancer induces 
the internalization of the substance 
P receptor, and c-fos expression in 
lamina I neurons, as well as behaviors 
indicative of pain (allodynia). 
2. This model is representative of 
the basic mechanisms involved in 
the mediation of bone cancer pain. 
This was shown by selectively block-
ing the aberrant osteoclastic activity, 
that accompanies cancer growth in 
the bone, by osteoprotegerin (OPG). 
Osteoprotegerin is a decoy receptor 
that inhibits osteoclasts by binding a 
specific ligand (OPGL) that activates 
them. Osteoprotegerin inhibits bone 
destruction by osteolysis, the neuro-
chemical reorganization of the spinal 
cord, as well as the behavioral manifes-
tations of pain.
The correlation between anatomical 
progression and behavioral manifes-
tations of pain, as well as similarities 
in the relative potency of treatments 
needed to suppress pain, indicate 
also the fact that this model simulates 
reliably several features of the clini-
cal disease in humans. With regards 
to the latter, it has been shown that 
both the pain behavior induced in the 
mouse model of  bone cancer pain, as 
well as the clinical pain in humans with 
bone metastases, are equally poorly 
responsive to opioids, compared to 
inflammatory pain (37). These observa-
tions validated the mouse metastatic 
bone pain model as adequate to eluci-
date mechanisms responsible for bone 
cancer pain, as well as the pertinent 
pharmacology, which may guide the 
development of new drugs to fight this 
type of pain (38).
Other cancer pain models
Variations of the cancer bone pain 
model developed by Mantyh’s group, 
are the models of tumor-induced bone 
destruction and hyperalgesia, pro-
duced by implantation of sarcoma cells 
into the mouse humerus or calcaneus 
bones. In these latter models, oste-
olysis begins six days after inocula-
tion and also correlates well with the 
development of hyperalgesic behavio-
ral responses (34, 39).
Information derived from 
the mouse bone cancer 
pain model
Utilizing the mouse metastatic bone 
pain model, the following information 
has been derived:
The role of osteoclasts.
Osteoclasts play a key role in the patho-
genesis of pain. Osteoclasts are highly 
differentiated multinucleated cells, 
derived from monocytte lines, that play 
a role in normal bone remodeling by 
bone resorption . In metastases to 
bones, what primarily mediates bone 
destruction and pain is aberrant activa-
tion of osteoclasts. 
In the bone cancer pain model, within a 
few days after tumor injection, a marked 
increase in the number of osteoclasts 
occurs, associated also with signs 
of maturation (such as presence of 
multiple nuclei) (40). Proliferation and 
hypertrophy of osteoclasts develops in 
both osteolytic and osteoblastic types 
of metastatic cancer disease. Active 
osteoclasts in contact with mineralized 
bone are continually internalizing prod-
ucts of mineralization, thus destroying 
the bone, and leading to pain via sev-
eral specific mechanisms:
1. Altered bone remodeling and 
mechanical instability. As a result of 
the activity of the osteoclasts leading 
to osteolysis, normal bone architecture 
and structural integrity is disrupted, 
leading to mechanical instability of the 
bone. Certain parts of the bone, such 
as the periosteum and bone marrow, 
contain a rich innervation by periph-
eral sensory neurons. The disruption 
of mechanical stability of the bone may 
produce mechanical deformation of 
the periosteum, which results in pain 
by stimulation of mechanoreceptors 
present on the sensory neurons that 
densely innervate it, as well as the 
bone. Deformation of the periosteum 
may thus generate intense, sharp pain 
from stimulation of these mechanore-
ceptors (41). 
2. Local extracellular acidosis. Osteo-
clastic activity leads to release of pro-
tons (H+) and the development of an 
acidic extracellular micro-environment 
(pH 4.0-5.0) in the vicinity of osteoly-
sis. This is essential for the osteoclast-
mediated bone resorption, but also 
stimulates pH-sensitive nociceptors, 
which extensively innervate the bones, 
thus producing pain. Additionally, pro-
tons may be released directly by the 
tumor cells, as well. Low extracellular 
pH is a characteristic feature of tumors, 
and especially those with necrosis. On 
the other hand, sensory neurons medi-
ating pain express a variety of channels 
that can open as a response to sensing 
protons. These include the transient 
receptor potential vanilloid 1 (TRPV1) 
and the acid sensing ion channel 3 
(ASIC 3) channels, which are sensitized 
and activated as a result of pH drop 
after accumulation of protons. Thus 
noxious stimulation by acidosis may 
initiate pain signaling mediating cancer 
pain (30, 42-44). 
3. Release of pro-algesic factors. 
Osteolysis produced by activated oste-
oclasts, results in release of growth 
factors, such as tumor growth factor β 
(TGF-β), which are normally contained in 
the bone (45, 46). These growth factors 
can directly activate nociceptors and 
produce pain (47). Other pro-hyper-
algesic peptides, such as dynorphin, 
associated with chronic pain states 
induced by peripheral nerve injury (48, 
49)  are also up-regulated by bone can-
cer pain.
4. Nerve injury. Excessive activity of 
the osteoclasts may also result in direct 
injury of peripheral sensory fibers, thus 
leading to neuropathic pain. This has 
been shown by Sevcik et al who docu-
mented a significant up-regulation of 
activating transcription factor 3 (ATF-3), 
a marker of nerve fiber injury, by meta-
static bone cancer pain (40).
5. Inflammation. Within a tumor mass, 
in addition to malignant cells, several 
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other cell types may be contained, such 
as inflammatory cells. Tumor-associat-
ed macrophages have been estimated 
to comprise a considerable portion (2–
60%) of the total tumor mass (50, 51). 
This is also the case in the mouse bone 
cancer pain model, wherein 5–10% 
of the mass have been macrophages 
(52). Inflammatory cells and malignant 
cells secrete a variety of substances 
that sensitize or excite primary afferent 
nociceptors. These mediators include 
but are not limited to prostaglandins, 
cytokines, and various growth factors 
such as epidermal growth factor, nerve 
growth factor, transforming growth fac-
tor and platelet-derived growth factor. 
These mediators have the capacity to 
sensitize and/or excite primary afferent 
nociceptors, thus contributing to clini-
cal pain and hyperalgesia (26-28, 53). 
Prostaglandins, highly involved in noci-
ceptive processes and mediation of 
pain, have been shown to be released 
at high levels by tumors and tumor-
associated macrophages, that express 
high levels of cyclo-oxygenase (42). 
Thus, NSAIDs may have a significant 
therapeutic role in the management of 
cancer pain. 
6. The role of nerve growth factor 
(NGF) and endothelin. Specific atten-
tion and attempts aiming at pharmaco-
logical suppression have focused on 
NGF and endothelin-1. The potentiating 
role of NGF in mediating inflamma-
tory and neuropathic pain states has 
been well recognized (54-57), as well 
as the antihyperalgesic effect of NGF 
sequestration (55). Secretion of NGF 
by tumor cells has been also implicated 
in the pathophysiology of cancer pain 
(58). The results of a study, wherein 
anti-NGF therapy produced signifi-
cant analgesia, as well as reversed 
indices of peripheral and central sen-
sitization in the mouse bone cancer 
pain model, indicate the potential role 
of NGF as a mediator of neural sen-
sitization and mediator of pain (59). 
Cancer tumors express high levels of 
a family of vasoactive peptides, called 
endothelins. Plasma levels of endothe-
lins have been associated with pain 
severity in cancer patients (60). Release 
of endothelin-1 from tumor cells (34) 
has been implicated in the induction of 
thermal hyperalgesia. Furthermore, in 
the same model of bone cancer pain in 
mice, tumor growth has been reported 
to induce development of spontaneous 
electrical activity and sensitization of C-
fibers, which provide innervation in and 
around the affected bone (35). It has 
been shown that some small unmyeli-
nated primary afferent fibers express 
endothelin receptors, the activation of 
which may result in sensitization or exci-
tation (61).
7. Glial activation resulting from the 
bone cancer pain. The role of activa-
tion of glial cells, such as astrocytes, 
has gained recently significant recogni-
tion as contributing to the pathogen-
esis of chronic pain (62, 63). Painful 
osteolytic destruction of the femoral 
bone as a result of experimental tumor 
growth results in ipsilateral hypertro-
phy of astrocytes in the spinal cord, as 
measured using the glial fibrillary acidic 
protein (GFAP) marker (29, 64, 65).
Data guiding treatments 
for bone cancer pain: 
translational implications.
Opioids. 
There is no doubt that pain from metas-
tases of tumors to the bones responds 
to opioids. In sarcoma-injected mice, 
El Mouedden and Meert demonstrated 
that acute treatment with fentanyl, suf-
entanil, and morphine, were effective 
in reducing bone cancer pain-related 
behaviors in a dose-dependent man-
ner (33).  Nevertheless, this analgesic 
response is rather poor compared to 
the responses in other types of pain 
(32). Morphine analgesia, also, does 
not affect limb use during forced ambu-
lation, which is decreased (as expect-
ed) in the bone cancer pain model 
(66). Only very high doses (40 mg/kg) 
produced some slight amelioration, 
consistent with other observations, as 
well (37). This may help explain the 
fact that pain with activity or movement 
in humans, suffering from metastatic 
bone disease, may often be resistant 
to analgesic therapy with opioids or 
require high doses for suppression.
Compared to inflammatory pain behav-
ior of the same intensity, mice need 
10 times more morphine for effective 
suppression of pain behavior induced 
by the bone cancer model (37). This is 
consistent with observations in humans 
suffering from metastases to the bones, 
requiring much higher doses of opio-
ids for pain control, compared to other 
types of pain. This very low potency of 
morphine to improve performance at 
forced ambulation (rotarod) may imply 
that the bone cancer pain model leads 
to some kind of ambulatory break-
through pain during forced ambula-
tion. Thus, it reproduces the observa-
tion that breakthrough pain episodes 
respond poorly to morphine in humans 
with advanced cancer, wherein the inci-
dence and severity of these episodes 
(especially during weight bearing or 
ambulation) increases with the magni-
tude of osteolytic damage (67).
Clinically, opioids effectively relieve can-
cer pain, although high doses have to 
be administered at times, especially to 
suppress incident “breakthrough” pain, 
or pain from nerve involvement. The 
direct effect of these commonly used 
drugs on tumor growth has been also 
investigated in vitro and in vivo. In vitro 
morphine has an inhibitory effect on 
growth of several human cancer lines, 
by suppression of tumor promoters, 
such as tumor necrosis factor α (TNF-
α) (68).  On the other hand, morphine 
may enhance tumor growth in animals 
inoculated with tumor cells (apparently 
via an immunosuppressant effect) (69), 
and reduce survival of rats with tumors 
(70). Clinically, ongoing, under-treat-
ed pain from cancer in humans may 
reduce survival by inducing a stress 
response with subsequent suppres-
sion of the immune system, a notion 
supported by experimental evidence in 
animals. Rats with painful stress from 
tumors exhibit reduced survival (71), 
while stress facilitates carcinogenesis 
in rats, in a fashion inhibited by opioid 
antagonists (72). Thus, whether opioids 
reduce or promote cancer growth is a 
matter of controversy.  
In this context, the question whether 
opioids aggravate or inhibit cancer 
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growth was investigated by Sasamura 
et al, who inoculated melanoma cells 
into the hind paw of mice. Animals 
developed hyperalgesic responses, 
of moderate intensity initially (between 
days 7-10 post injection) and subse-
quently of severe intensity (after two 
weeks post-injection), in parallel with 
swelling of the injected paw volume. 
Metastases to the lungs were evident 
after post-inoculation day 12. Com-
pared to control animals, mice treated 
with repeated subcutaneous morphine 
injections in doses that completely 
inhibited hyperalgesia, or sciatic neu-
rectomy (thus interrupting nociceptive 
traffic from the site of tumor growth), 
exhibited marked inhibition of tumor 
growth and lung metastases. These 
findings indicate that effective relief 
from cancer pain inhibits tumor and 
the progression of metastatic disease 
(73).  In the same study, diclofenac 
also inhibited the hyperalgesia at the 
early phases (during the first three 
weeks post-inoculation) indicating the 
relevant contribution of inflammatory 
mechanisms in the mediation of tumor-
induced hyperalgesic responses.
Considering the additional experi-
mental evidence that different types 
of stress may suppress immunity and 
enhance cancer growth and metastatic 
spread (74-78), as well as addition-
al evidence indicating that morphine 
analgesia attenuates surgery-induced 
enhancement of metastatic coloniza-
tion in rats (79), it is arguable that effec-
tive relief from pain by medication or 
neural blockade in cancer patients in 
addition to improving comfort and qual-
ity of life, does have the capacity to 
inhibit tumor expansion and metastatic 
spread as well. 
Biphosphonates
Biphosphonates relieve pain from 
metastases to bones. Biphosphonate 
compounds are drugs with high affinity 
to calcium ions that are contained in the 
hydroxy-apatite crystals of the bones, 
something that results in a significant 
distribution and binding of these drugs 
into the mineralized bone tissue (more 
than 50% even after a single dose) (80). 
At these sites, they have the capacity 
to suppress the activity of the osteo-
clasts, and consequently to inhibit bone 
resorption and lysis (81). Thus, they 
are helpful in the management of oste-
oporosis, as well as in the treatment 
of tumor-induced osteolysis and bone 
cancer pain. 
This was also shown experimentally in 
the mouse bone cancer pain model, 
wherein alendronate, a biphosphonate 
compound, decreases pain, as well as 
destruction of bone and sensory nerve 
fibers, produced by the uncontrollable 
activation of the osteoclasts. Sevcik et 
al injected osteolytic sarcoma cells, sta-
bly transfected with green fluorescent 
protein (GFP), into the intramedullary 
space of the mouse femur. Mice were in 
parallel treated with alendronate (chron-
ically, from the time of the injection until 
bone cancer pain became severe), or 
vehicle (40). Sarcoma-injected animals 
developed a significant spontaneous 
and evoked pain behavior, which was 
significantly attenuated by alendronate. 
Alendronate also facilitated limb use, 
ambulation, and tolerance of palpation 
or pressure. Improvement in behavio-
ral parameters, paralleled the attenu-
ation of markers indicative of periph-
eral or central sensitization, induced 
by the tumor. Specifically, alendronate 
reduced the levels of ATF-3, a marker 
of neuronal injury. It also attenuated the 
expression of galanin, which was sig-
nificantly increased in vehicle-treated, 
sarcoma-injected rats. Galanin levels 
increase in peripheral sensory neu-
rons in several chronic pain models 
(82). GFAP labeling in the spinal cord, 
indicative of glial activation by astrocyte 
hypertrophy by bone cancer pain in 
sarcoma-injected animals, was sig-
nificantly attenuated by alendronate, 
compared to vehicle-treated mice. 
Finally, treatment of sarcoma-injected 
mice with alendronate significantly 
decreased galanin (which is involved 
in the maintenance of chronic pain, 
and was upregulated in the sarcoma-
injected, vehicle-treated mice). Finally, 
it was shown that alendronate reduces 
tumor-induced bone destruction, via 
decreasing the number of activated 
osteoclasts without affecting their total 
number. Alendronate treatment did not 
change viable tumor load (defined as 
the percent of the intramedullary space 
occupied by viable, non-necrotic tumor 
tissue), although both tumor growth 
and tumor necrosis increased. 
Biphosphonates may exert analgesic 
effects via other mechanisms as well, 
not related to the inhibitory effects on 
osteoclasts. These drugs have been 
shown to relieve pain in peripheral neu-
ropathic pain syndromes, of non-malig-
nant etiology, such as complex regional 
pain syndromes (83, 84). Kawabata et 
al reported that etidronate and alen-
dronate suppress adjuvant-induced 
mechanical allodynia in rats, which 
might be clinically relevant. Anti-allo-
dynic effect of biphosphonates was 
reversible by glibenclamide in a fash-
ion suggesting involvement of adeno-
sine triphosphate-sensitive potassium 
(KATP) channels (85). These channels 
are present on peripheral sensory neu-
rons and are involved in the pathophysi-
ology of nociception and neuropathic 
pain (86), so that their activation by 
biphosphonates may induce a periph-
eral analgesic effect, as well.
Osteoprotegerin
Osteoprotegerin (OPG), a molecule 
that belongs to the soluble tumor necro-
sis factor (TNF) receptor superfamily 
(87-89) seems to be a very promising 
candidate as a potential therapeutic 
agent in the management of bone can-
cer pain. Osteoprotegerin acts as a 
secreted decoy receptor that binds to, 
and thus sequesters a cognate ligand, 
the OPG ligand (OPGL). The bound, 
sequestered ligand is thus prevented 
from activating its cellular target, which 
is the receptor activator of nuclear 
factor-Κ  (RANK receptor), a specific 
receptor expressed on mature osteo-
clasts. The RANK receptor is essential 
for the function of osteoclasts, because 
it mediates their activation and bone 
resorption.
The OPG ligand in the adult is derived 
mainly from the osteoblasts, as well as 
from activated T cells. Osteoblasts are 
cells essential in the bone remodeling, 
by directly producing new bone forma-
tion, as well as by secreting the OPG 
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ligand which subsequently regulates 
the bone resorption by stimulating by 
the osteoclasts (90). Thus osteoclas-
tic acticity is coupled to osteoblastic 
activity, resulting in a balanced bone 
remodeling process. This normal proc-
ess of remodeling is however disrupted 
in bone cancer resulting in aberrant and 
out of proportion bone destruction and 
pain. Immune T cells may be also acti-
vated by cytokines and growth factors 
released by tumor cells, and also be 
a source of OPG ligand release. Con-
sidering the capacity of OPG ligand to 
stimulate osteoclasts, it is an important 
mediator of bone cancer pain, wherein 
bone damage and hyperalgesia are 
mediated by increased activity of the 
osteoclasts. 
Honore et al, employing the mouse 
bone cancer pain model, reported that 
treatment with OPG completely abol-
ishes cancer-induced bone destruc-
tion, reduces the number of osteo-
clasts at sites of tumor, substantially 
suppresses spontaneous and evoked 
pain-related behaviors, and finally pre-
vents the neurochemical reorganization 
of the spinal cord seen in mice with 
bone cancer pain (38, 91).  The lat-
ter action of osteoprotegerin includes 
attenuation of dynorphin immunoreac-
tivity in laminae III-IV neurons, reduced 
c-fos immunoreactivity in neurons in 
laminae V-VI, as well as reduced GFAP 
in laminae I-X, (indicative of blocked 
astrocyte hypertrophy in the spinal cord 
by OPG). Palpation induced substance 
P release, substance P receptor inter-
nalization, and palpation-induced c-fos 
expression seen in the spinal cords 
of sarcoma-injected mice were also 
blocked by osteoprotegerin. The action 
of OPG was rapid. Within 2 days after a 
single injection there was a substantial 
inhibition of bone absorption, but in 
this study it was administered as daily 
subcutaneous injections (91). 
The mechanism of action of OPG, on 
blocking cancer-induced bone destruc-
tion and pain via inhibition of the actions 
of OPG ligand on osteoclasts, is sup-
ported by the observation that OPG 
eliminates activated osteoclasts at the 
site of the tumor growth, as well as 
tumor induced osteolysis, but has no 
substantial effect on the tumor growth 
itself. Nevertheless, in the mice treated 
with OPG, pain was reduced in parallel 
with the reduction of bone damage. 
The potential of OPG as a very prom-
ising therapeutic agent against can-
cer pain remains to be investigated in 
human patients. OPG so far seems 
to be free of any side effects, and has 
actually been successfully adminis-
tered in postmenopausal women for the 
management of osteoporosis (92).  
Non-steroidal anti-inflammatory drugs 
and acetaminophen
NSAID are frequently used as anal-
gesics in cancer patients. Saito et al 
employing the mouse bone cancer 
pain model investigated the pharma-
cological efficacy of selective COX-
1 or COX-2 inhibitors, non-selective 
COX inhibitors, acetaminophen and 
morphine on bone cancer pain. Anal-
gesia was assessed after drugs were 
administered 2 weeks post-injection 
of sarcoma cells into mouse femur (a 
time point at which radiographic exami-
nation demonstrated severe destruc-
tion of the injected femur, associated 
with significant pain-related behaviors). 
Oral administration of acetaminophen, 
indomethacin, and morphine, but not 
of SC560 (a COX-1 selective inhibi-
tor) or celecoxib, produced an anal-
gesic effect, while co-administration of 
subanalgesic doses of morphine with 
acetaminophen enhanced the analge-
sic effect of the latter (93). Thus, experi-
mental evidence was provided support-
ing the efficacy of the classical (but not 
selective COX inhibitors) against bone 
cancer pain. 
Diet
Alternative therapies, some of them 
based on diet alterations, are recently 
emerging as part of cancer pain man-
agement on a more frequently basis. 
Zhao et al investigated the effect of the 
type of diet on three experimental mod-
els of bone cancer pain by inoculation 
of sarcoma cells into the intramedullary 
space of the mouse humerus, femur or 
calcaneus.  Diets based on casein or 
soy proteins had no impact on param-
eters reflecting cancer growth, nor did 
affect the antihyperalgesic pharmaco-
logical effect of morphine. However, 
mice subjected to the femur bone can-
cer pain model exhibited significantly 
less mechanical hyperalgesia. So it is 
likely that soy diet may be beneficial in 
bone cancer pain (39). 
Anti-NGF therapy
Because NGF release by tumor cells 
has been implicated as a possible 
mediator of cancer pain, Sevcik et al 
investigated the therapeutic potential of 
anti-NGF therapy employing the mouse 
model of bone cancer pain (59). Both 
spontaneous and movement-induced 
pain behaviors were attenuated by a 
novel antibody that sequesters NGF 
(anti-NGF, mAb 911, Rinat Neuro-
science Corp., Palo Alto, CA, USA), in 
a magnitude greater than that of high 
dose morphine. Several neurochemical 
changes indicative of peripheral and 
central sensitization were also reduced 
by this therapy: The expression of ATF-
3, a marker of nerve injury, is attenu-
ated, activated macrophage infiltra-
tion is limited, while at the spinal cord 
dynorphin expression and immediate 
early gene activation (upregulated in 
sarcoma injected mice) is reduced, 
too. The results of this study indicate 
that anti-NGF therapy is particularly 
effective in blocking bone cancer pain, 
but efficacy in humans remains to be 
determined clinically. 
Endothelin receptor antagonists
Because endothelins, acting on specific 
receptors present on the membrane of 
a subpopulation of small unmyelinated 
primary afferents, sensitize these nocic-
eptors thus mediating cancer pain, their 
antagonism may have a role in cancer 
pain management. In the mouse bone 
cancer pain model, an endothelin A 
receptor selective antagonist produced 
significant alleviation of spontaneous 
and evoked pain behaviors after acute 
or chronic administration. The latter also 
resulted in attenuation of peripheral and 
central sensitization (94). This provides 
a target for therapeutic interventions, 
considering the role of endothelins in 
clinical pain as well (34).
Bradykinin antagonists
In the mouse bone cancer pain model, 
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Sevcik et al showed that spontaneous 
and movement evoked pain behav-
iors may be significantly attenuated by 
blockade of the bradykinin B1 receptor, 
even in advanced bone cancer (95). 
Peripheral sensory neurons normally 
express both B2 (at high levels) and B1 
receptors (at low levels), but the latter 
get up-regulated following peripheral 
inflammation or injury, such as tumor-
induced (42). In these cases, also, 
bradykinin released by tumor cells may 
be associated with increased receptor 
activation, resulting in pain.
Gabapentin
Gabapentin, a novel anticonvulsant with 
antihyperalgesic effectts, acting as an 
inhibitor of voltage-gated calcium chan-
nels (96) that control neurotransmitter 
release on peripheral sensory neurons 
(97), is used widely in the manage-
ment of pain originating from peripheral 
nerve injury (98, 99). 
Sensory fibers innervating the affected 
femur have been shown to become 
sensitized and injured, following inocu-
lation of sarcoma cells in the mouse 
bone cancer pain model. The tumor-
induced sensory nerve injury is char-
acterized by upregulated expression of 
activating ATF3 in the nuclei of injured 
neurons (a specific marker of nerve 
injury), increased expression of galanin 
on sensory neurons, as well as signs 
of glial activation and hypertrophy of 
satellite cells and macrophage infiltra-
tion within the ipsilateral dorsal root 
ganglia. These changes are accom-
panied by behavior manifestations of 
spontaneous and movement-induced 
pain. Chronic treatment with gabapen-
tin, without affecting bone destruction 
or tumor growth, attenuated both spon-
taneous and movement-evoked bone 
cancer pain behaviors, thus justifying 
its use as a potential adjuvant in bone 
cancer pain (100). Similar results have 
been shown also by Donovan-Rod-
riguez et al in another study employing 
a metastatic bone cancer pain model 
(101). In this study cancer induced 
bone pain was established in rats after 
inoculating cancer cells into the tibia, 
resulting in neuronal hyper-excitability 
at the superficial dorsal horns of the 
spinal cord, accompanied by behavio-
ral manifestations of pain. Gabapentin 
administered acutely and chronically 
normalized the hyperexcitable super-
ficial dorsal horn neuronal response, 
significantly reducing electrical-evoked 
and mechanical-evoked (but not 
thermal-evoked) responses. Chronic 
administration of gabapentin also sig-
nificantly attenuated pain behavior in 
injected rats, restoring responses to 
preoperative baseline degrees. 
Results demonstrating an analgesic 
effect of gabapentin against cancer-
induced pain have been shown by 
Kuraishi et al, in another cancer pain 
model, after orthotopic inoculation of 
melanocytes into the plantar region 
of mouse hind paw. This produced 
marked tactile allodynia and mechani-
cal hyperalgesia, which were inhibited 
by oral gabapentin without effects on 
gross behaviors. Diclofenac, mexilet-
ine, clonidine and suramin were without 
effects on allodynia and hyperalgesia. 
Subcutaneous injections of and NG-
nitro-L-arginine methyl ester were also 
without effects. Repeated administra-
tion of gabapentin (150 mg/kg, p.o.) 
produced constant inhibitions, sug-
gesting no analgesic tolerance (102). 
These studies indicate the potential of 
gabapentin as a useful adjuvant drug in 
the management of cancer pain.
Clinical management of 
cancer pain. What is the 
evidence? 
Pain secondary to cancer is complex 
and its treatment should be individualized 
in order to achieve optimum effect. Suc-
cessful management depends upon 
understanding of all factors possibly 
involved in mediating and sustaining 
pain in a particular individual, as well 
as upon familiarity with all established 
and novel therapeutic approaches. 
Systemic pharmacologic management 
aiming at reducing nociceptive input, 
modulating transmission of pain to 
the central nervous system, or altering 
central perception of pain remains as the 
mainstay of the treatment. The classical 
algorithm based on the analgesic ladder 
introduced by the WHO (103) provides 
a general frame of action, so that no 
cancer patient should live or die with 
unrelieved pain (104) (105). 
The three-step analgesic ladder 
includes the regular administration of 
non-opioid analgesics for mild pain 
(step 1), weak opioids for mild to mod-
erate pain (step 2),  and long-acting 
strong opioids (round the clock) with 
immediate-acting opioids (as needed 
for breakthrough pain) for moderate to 
severe pain (step 3).  The ladder also 
mandates the use of non-opioid anal-
gesics (NSAIDs), adjuvant drugs (such 
as anticonvulsants, antidepressants or 
corticosteroids) and additional meas-
ures for pain relief, when appropriate 
(106). These non-opioid analgesics and 
adjuvants need to be included at each 
step of the WHO ladder, if pain cannot 
be treated adequately by the standard 
analgesics alone (107). Proper use of 
the WHO three step analgesic ladder 
provides effective relief in the majority of 
cancer patients with pain (106).
The appropriate selection of adjuvants 
(such as anticonvulsants, like gabap-
entin, to control neuropathic manifesta-
tions, and/or tricyclic antidepressants, 
which provide additional analgesic effi-
cacy against certain types of pain or 
other symptoms like insomnia or depres-
sion) should be guided by proper iden-
tification of the exact nature of pain, and 
an attempt to establish a diagnosis as 
precise as possible with regard to exact 
nature of the painful syndrome. Some-
times, failure to achieve therapeutic 
efficacy may be secondary to pharma-
cokinetic reasons, such as inadequate 
route of administration. The latter may 
be corrected by choosing more suit-
able routes, such as transdermal and 
transmucosal fentanyl in patients with 
poor absorption of oral opioids from 
the gastrointestinal tract. Furthermore, 
when advancing into higher steps of 
the analgesic ladder a reassessment is 
necessary whether adjuvant and non-
opioid analgesics are necessary. Not 
infrequently, discontinuation of these 
drugs may result in worsening of pain, 
because certain types of pain may be 
particularly responsive to these drugs. 
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Most neuropathic pain syndromes 
are resistant to opioids (108) but may 
respond adequately to gabapentin (98, 
99) or antidepressants (109-111) . Fur-
thermore, combinations of analgesics, 
such as gabapentin with opioids, result 
in synergistic effects which potentiate 
the analgesic benefit of each compo-
nent (112) . Finally, any therapeutic plan 
should also include the use of physical 
therapy, psychotherapeutic, spiritual 
or religious, as well as anesthetic inter-
ventional (113-116) and neurosurgical 
approaches, whenever necessary. 
The new models of cancer pain have 
recently facilitated a mechanism-based 
understanding of the factors that gener-
ate and maintain cancer pain as well as 
pertinent pharamcology. Findings from 
these studies have the potential to pro-
vide new mechanism-based therapies 
that may improve the quality of life and 
survival of cancer patients, but even-
tually therapies need to be endorsed 
by accumulating evidence, such as 
that provided by converging lines of 
research. Systematic reviews of the 
best available evidence on cancer pain 
management is a valuable source of 
information guiding the implementation 
of novel therapies or the continuing 
application of existing ones (117). The 
availability of such reviews on pain man-
agement and palliative care is increas-
ing through the efforts of groups such 
as the Cochrane Collaboration. The 
dissemination of pertinent evidence to 
health professionals dealing with can-
cer patients with pain has the potential 
of improving the quality of patient care. 
Preventative treatments
Pain related to cancer and its treat-
ments may be prevented by suitable 
preventative strategies. Studies by 
Fassoulaki et al. have demonstrated 
that suitable perioperative analgesic 
regimens, mainly based on multimo-
dal analgesic techniques, can signifi-
cantly reduce the incidence and sever-
ity of chronic post-mastectomy pain in 
women after breast surgery for cancer 
(15-18). These regimens are based on 
the concomitant perioperative use of 
gabapentin, sodium channel blockers 
(administered topically or systemically) 
and local anesthetics administered 
topically or in nerve infiltrations.
Opioid analgesia for 
cancer pain
Wiffen et al conducted a systematic 
review in order to assess the efficacy 
of oral morphine in relieving cancer 
pain, as well the incidence and severity 
of side effects (118). Forty five pub-
lished randomized controlled studies 
(on 3061 subjects) were included in the 
meta-analysis, in which morphine was 
shown to be an effective analgesic for 
cancer pain. Pain relief did not differ 
between sustained-release and imme-
diate-release morphine formulations. 
Sustained release morphine doses 
were effective for 12 or 24 hour dosing, 
depending on the formulation. Adverse 
effects were not uncommon but only 
4% of patients discontinued treatment 
because of intolerable adverse effects.
Methadone, a synthetic opioid, seems 
to offer certain pharmacokinetic and 
pharmacodynamic advantages over 
morphine in the context of cancer pain 
management (119), including longer 
half life, as well as a weak inhibitory effect 
on the N-methyl-d-aspartate (NMDA) 
receptor (120). The implications of the 
latter action may be a lower propensity 
to induce tolerance or opioid-induced 
hyperalgesia, and some suppression 
of signaling mechanisms leading to 
central sensitization. Nevertheless, the 
pharmacokinetic behavior of this drug 
is characterized by unpredictability and 
significant inter-individual variability, 
indicating extreme caution it its dosage 
titration. With regards to cancer pain 
management, Nicholson conducted a 
relevant systematic review on eight ran-
domized controlled trials of methadone 
against active or placebo comparator 
in patients with cancer pain (five double 
blinded, two crossover with 356 recruits 
and 326 completing patients)(121). 
Methadone’s analgesic efficacy was 
shown to be similar to that of morphine 
while adverse events were also similar 
in incidence and severity to those expe-
rienced with morphine. Nevertheless, 
the majority of studies involved single 
dose comparisons or short-term use, 
something that may overlook the poten-
tial of methadone accumulation leading 
to delayed onset of adverse effects with 
chronic administration. Fixed interval 
dosing schedules conducted over sev-
eral days are associated with a high risk 
of serious morbidity and mortality. The 
complex and highly individual pharma-
cokinetics of methadone require that 
experienced clinicians take responsibil-
ity for initiating, titrating and monitoring 
this drug.
Breakthrough pain is a common and 
distinct component of cancer pain with a 
negative impact on quality of life. Break-
through pain is a transient increase in 
the pain intensity over the background 
pain:  usually breakthrough pain is of 
rapid onset, severe in intensity, and 
generally self-limiting with an average 
duration of 30 minutes. At present the 
current approach to managing break-
through pain is using supplemental 
analgesia (also known as “rescue” anal-
gesia), employing immediate-release 
medication at a dose proportional to 
the total around-the-clock opioid dose. 
The problem is that not-infrequently 
immediate-release opioids, such as 
immediate-release morphine, may fail 
to produce prompt analgesia. Inability 
to swallow or poor absorption from the 
gastrointestinal tract have been impli-
cated, thus indicating the need for alter-
native (preferably non-invasive) routes 
of administration.
Zeppetella and Ribeiro assessed the 
evidence for the use of opioids in the 
management of breakthrough pain in 
cancer patients, by looking at four stud-
ies (393 participants) investigating with 
the use of oral trans-mucosal fentanyl in 
the management of breakthrough pain 
(122). Oral trans-mucosal fentanyl was 
shown to be an effective analgesic for 
breakthrough pain, superior to placebo 
and morphine. Pain intensity scores 
were lower and pain relief scores were 
higher for patients receiving oral trans-
mucosal fentanyl at all times, as well as 
global assessment indices (122). 
Development of unwanted phenomena 
associated with the chronic use of opio-
ids, such as side effects associated 
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with high doses, tolerance, and hyper-
algesia, may provide a hindrance to 
their continuing use on certain patients. 
In these cases, ketamine, an anesthet-
ic and analgesic agent with a partial 
antagonist effect on the NMDA recep-
tor, may be helpful as an adjuvant to 
opioids, but its use may be limited by 
psychomimetic effects. Bell et al deter-
mined the effectiveness and adverse 
effects of ketamine as an adjuvant to 
opioids in the treatment of cancer pain, 
by looking at four randomized con-
trolled trials and 32 case studies/case 
series reports, comparing ketamine to 
placebo or active control (123). Two 
eligible trials concluded that ketamine 
improves the efficacy of morphine in 
the treatment of cancer pain, at the 
expense of hallucinations in some 
patients. Hallucinations may also occur 
in morphine alone. However, consider-
ing the small number of patients and 
the significant heterogeneity in these 
studies, it is not possible to conclude 
with certainty about the benefits and 
harms of ketamine as an adjuvant to 
opioids for the relief of cancer pain. 
Non-steroidal anti-inflam-
matory drugs (NSAIDs) 
and/or acetaminophen for 
cancer pain
Non-steroidal anti-inflammatory agents 
are widely used to treat cancer pain, 
alone –in the initial WHO analgesic lad-
der step-, or in combination with opio-
ids –in the subsequent steps. In order 
to assess which agent is most clinically 
efficacious for relieving cancer-related 
pain, or even what may be the addi-
tional benefit of combining an NSAID 
with an opioid in this setting, McNicol et 
al looked at 42 pertinent trials involving 
3084 patients, in a qualitative system-
atic review (124). They concluded the 
following:
1. NSAIDs appear to be more effective 
than placebo for cancer pain; 
2. There is no clear evidence to support 
superior safety or efficacy of one NSAID 
over another; 
3. Trials of combinations of an NSAID 
with an opioid have shown either no 
difference (4 out of 14 papers), a statis-
tically insignificant trend towards supe-
riority (1 out of 14 papers), or at most a 
slight but statistically significant advan-
tage (9 out of 14 papers), compared 
with either single entity. 
4. No generalizations can be made 
regarding efficacy and safety of NSAIDs 
for cancer pain.
It seems likely that particular subpopu-
lations of patients suffering from can-
cer pain may particularly benefit from 
inclusion of NSAIDs in their analgesic 
regimen. These may be patients with 
painful metastatic disease affecting the 
bones or patients with significant pain, 
mediated by predominant inflammatory 
mechanisms. However, this needs to 
be confirmed by additional evidence.
Biphosphonates
Certain malignancies (such as breast 
cancer, kidney cancer, thyroid cancer, 
multiple myeloma) are very frequently 
complicated by metastatic disease or 
lytic lesions affecting the bones. Bony 
metastatic disease, in particular, affects 
more than half of women with breast 
cancer during the course of their dis-
ease, and management of pain arising 
from this condition may be challeng-
ing. Tumors that compromise bone 
or nervous structures due to the bone 
destruction process may be very pain-
ful. As mentioned above, pain occurs 
as a result of bone destruction and, as 
more destruction ensues, more pain 
can be experienced. Functional limita-
tion and neurological impairment may 
be additional problems. Relief of pain 
from bone metastases is based on 
treating the cancer itself, radiotherapy, 
conventional analgesics (opioids and/
or NSAIDs) and specific drugs such as 
biphosphonates, calcitonin or radioac-
tive agents. 
In the mouse bone cancer pain model 
it has been clearly demonstrated that 
biphosphonate compounds inhibit 
osteoclast-mediated bone resorption, 
and suppress associated pain behav-
iors (40). Therapeutically they have a 
role in treating painful metastatic dis-
ease involving bones, as well as tumor 
related hypercalcemia. Pavlakis et al 
reviewed the clinical efficacy of biphos-
phonates in treating bone pain, quality 
of life and survival in 2189 women with 
early and advanced breast cancer by 
looking at 21 randomized studies (125). 
In women with advanced breast cancer 
and clinically evident bone metastases, 
the use of bisphosphonates (oral or 
intravenous) reduces the risk of devel-
oping an adverse skeletal event such as 
pathological fracture, as well as delays 
the time to skeletal event. The bisphos-
phonate most effective in reducing the 
risk of developing a skeletal event by 
41% was intravenous zolendronate (4 
mg). Bisphosphonates may also signifi-
cantly reduce bone pain in women with 
advanced breast cancer and clinically 
evident bone metastases, thus improv-
ing global quality of life. Nevertheless, 
treatment with bisphosphonates does 
not appear to affect survival in women 
with advanced breast cancer. Toxic-
ity associated with bisphosphonates is 
generally mild and infrequent.
Yuen et al reviewed the efficacy of 
bisphosphonates in relieving pain in 
patients with bone metastases from 
prostate cancer, in 10 randomized 
controlled studies that involved 1955 
patients (126). Response rates to treat-
ment were higher for the treatment 
group, showing a trend of improved 
pain relief in the bisphosphonate group, 
while the rates for skeletal events, such 
as pathological fractures, were lower for 
the treatment group, as well. A signifi-
cant increase in nausea was observed 
in patients who received bisphospho-
nates compared to placebo, but no 
increase in other adverse events was 
observed. There was no statistically sig-
nificant difference between the bisphos-
phonate group and the control group in 
terms of prostate cancer death, disease 
progression, radiological response and 
prostate specific antigen (PSA) levels. 
Regarding the choice of bisphospho-
nates or the dose and the route of 
administration, there are insufficient 
data so far. Therefore, bisphospho-
nates should be considered for patients 
with metastatic prostate cancer for the 
treatment of refractory bone pain and 
prevention of skeletal events, but more 
research is needed to guide the choice 
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of bisphosphonates, optimal treatment 
schedule as well as cost-benefit com-
parisons. 
Djulbegovic et al, in addition, reviewed 
whether adding bisphosphonates to 
standard therapy in multiple myeloma 
decreases skeletal-related morbidity 
(pathological fractures), skeletal-relat-
ed mortality, as well as overall mortality 
(127). They also determined the effects 
of bisphosphonates on pain, quality of 
life and incidence of hypercalcemia. 
They looked at 11 randomized trials, 
investigating the use of bisphospho-
nates in myeloma (1113 patients) com-
pared with placebo or no treatment as a 
control group (1070 patients). Analysis 
demonstrated that bisphosphonates 
are beneficial in preventing pathologi-
cal vertebral fractures and in providing 
relief from pain. The benefit was most 
apparent with clodronate and pamidro-
nate. However, there was no significant 
effect of bisphosphonates on mortality, 
on the reduction of non-vertebral frac-
tures, or on the incidence of hypercal-
cemia. There were also no significant 
adverse effects associated with the 
administration of bisphosphonates. 
Calcitonin
The hormone calcitonin, by limiting 
osteoclastic activity, has the potential 
to relieve pain in  non-malignant chron-
ic pain conditions (such as complex 
regional pain syndromes, Paget’s dis-
ease and osteoporosis) (128-130), in 
cancer patients (131), and also to retain 
bone density, thus reducing the risk of 
fractures. Martinez et al assessed the 
effectiveness of calcitonin in control-
ling metastatic bone pain and reducing 
bone complications (hypercalcemia, 
pathological fractures and nerve com-
pression) in patients with bone metas-
tases (132). Of the two small stud-
ies included in the review, one study 
showed a non-significant effect of calci-
tonin in the number of patients with total 
pain reduction, while the second study 
provided no evidence that calcitonin 
reduced analgesia consumption in 
patients with painful bone metastases. 
Overall, there was no evidence that 
calcitonin was effective in controlling 
complications due to bone metastases, 
improving quality of life, or patients’ 
survival. Furthermore, although not sta-
tistically significant, a greater number of 
adverse effects were observed in those 
who received calcitonin. So, the limited 
evidence currently available does not 
support the use of calcitonin to control 
pain from bone metastases. Never-
theless, some selected patients might 
benefit if other treatment options have 
failed.
Gabapentin
Basic studies, employing animal can-
cer pain models, indicate an analgesic 
effect of gabapentin against cancer 
pain, as well. It is likely that the drug 
possesses a generic analgesic and 
antihyperalgesic effect by modifying 
channels involved in nociception (86, 
96) and neurotransmitter release (133). 
Confirmation from clinical studies, have 
shown that gabapentin is effective 
against pain in cancer patients, as well 
(134-149).
Gabapentin can be particularly helpful 
in patients with neuropathic pain (burn-
ing pain, shooting pain, allodynia) due 
to cancer, particularly when pain does 
not respond to opioids (137, 142, 147, 
148, 150). Both pain and dysesthetic 
symptoms respond well to this drug, 
which also has an opioid sparing effect 
as well (142). Effective doses range 
between approximately 100 and 3000 
mg daily (144). Gabapentin has been 
also helpful in relieving abdominal pain 
from upper abdominal malignancies, 
such as pancreatic cancer infiltrating 
the celiac plexus, thus sparing the need 
for blockade of the latter structure (145). 
It is helpful in reducing pain associ-
ated with painful procedures in cancer 
patients (140), as well as in reducing 
myoclonic movements associated with 
the use of high doses of opioids in 
cancer pain (143). Side effects include 
mainly somnolence, drowsiness and 
headache (136, 142, 144).
Non-pharmacological 
management 
In addition to appropriate pharmaco-
therapy, relief of pain from bone metas-
tases can be achieved by treating the 
tumor using administration of radioac-
tive agents or radiation therapy. Thus, in 
order to determine the efficacy of radio-
isotopes to control pain in patients with 
bone metastases, complications due 
to bone metastases (hypercalcemia, 
pathological bone fracture and spinal 
cord or nerve compression), as well 
as its efficacy in terms of patient sur-
vival and adverse effects, Roque et al 
looked at randomized controlled trials 
that compared radioisotopes with pla-
cebo, and where the major outcome 
was either pain or complications of 
bone metastases assessed at least 
four weeks after treatment (151). Radio-
isotopes did actually have a small effect 
on pain with no difference in analgesic 
use. Leukocytopenia and thrombocyto-
penia were the main secondary effects 
associated with the administration of 
radioisotopes.
Radiation therapy is another therapeu-
tic modality frequently used for pallia-
tion against painful metastatic disease. 
Sze et al reviewed randomized studies 
comparing single fraction radiotherapy 
with multifraction radiotherapy on meta-
static bone pain relief and prevention 
of bone complications (152). Eleven 
trials that involved 3435 patients were 
identified. The overall pain response 
rates for single fraction radiotherapy 
and multifraction radiotherapy were 
60% and 59% respectively, indicating 
no difference between the two radio-
therapy schedules. There was also no 
difference in complete pain response 
rates for single fraction radiotherapy 
and multifraction radiotherapy. How-
ever, patients treated by single fraction 
radiotherapy had a higher re-treatment 
rate (with 21.5% requiring re-treatment) 
compared to 7.4% of patients who 
received multifraction radiotherapy. 
The pathological fracture rate was also 
higher in single fraction radiotherapy 
patients. Three percent of patients 
treated by single fraction radiotherapy 
developed pathological fracture com-
pared to 1.6% for those treated by mul-
tifraction radiotherapy. The spinal cord 




for pain control in cancer
The discovery of endogenous opioids 
and opioid receptors in the central nerv-
ous system (CNS) (153-155), and novel 
techniques of delivery, have allowed the 
optimization of opioid therapy by deliver-
ing the medication centrally (or neuraxi-
ally) rather than systemically in patients 
refractory to systemic treatments. These 
patients may obtain relief from neuraxial 
opioid therapy, by epidural, subarach-
noid or intra-cerebroventricular infusion. 
Ballantyne et al have compared intra-
cerebroventricular therapy with other 
neuraxial treatments and attempted to 
determine whether the former has any 
benefits over epidural or subarachnoid 
administration, in terms of efficacy, 
adverse effects, and complications. 
Their search did not retrieve any control-
led trials, so data from uncontrolled stud-
ies were used to compare incidences of 
analgesic efficacy, adverse effects, and 
complications. These reported excel-
lent pain relief among 73% patients who 
received intra-cerebroventricular infu-
sion, compared with 72% of patients with 
epidural, and 62% subarachnoid admin-
istration. Unsatisfactory pain relief was 
low in all treatment groups. Persistent 
nausea, persistent and transient urinary 
retention, transient pruritus, and con-
stipation occurred more frequently with 
epidural and subarachnoid infusions, 
while respiratory depression, sedation 
and confusion were most common with 
intra-cerebroventricular technique. The 
incidence of pump infection for epidural 
and subarachnoid administration was 
zero. Thus, neuraxial opioid therapy can 
be effective for managing pain not ade-
quately controlled by systemic treatment 
in cancer patients.
Various neurolytic procedures may be 
efficacious for pain control in cancer 
patients, if pharmacological manage-
ment fails, or is limited by uncontrol-
lable side effects, or for pain limited in 
certain anatomical areas, such as the 
upper abdomen. In the latter case, five 
randomized controlled trials support 
the efficacy of celiac plexus blocks for 
upper abdominal pain secondary to 
pancreatic or other cancer (117). 
Vertebroplasty is a novel procedure 
by which malignant lesions produc-
ing painful pathological fractures of 
the vertebral bodies can be treated. 
This procedure consists of fluoroscopi-
cally guided percutaneous injection of 
methyl methacrylate cement (or similar 
biomaterial) into the collapsed vertebral 
body. Vertebroplasty thus results in 
bone strengthening, structural resto-
ration and marked or complete pain 
relief in most cases (156-158). It also 
prevents the vertebra from further col-
lapse causing spinal cord compression 
(159, 160). The pain relief and vertebral 
consolidation have been attributed to 
the internal “casting” of the trabecular 
microfractures by the methyl methacr-
ylate injection (161). The main indica-
tions for vertebroplasty are osteolytic 
metastases and myeloma, painful 
hemangioma, and osteoporotic ver-
tebral fractures with intractable pain 
despite optimal medical treatment 
(156, 157, 162). This procedure does 
have a role in the management of pain 
in patients suffering from metastases 
to the spine, something supported by a 
large number of studies (156, 158, 160, 
162-170). Success rates, with regard to 
pain relief and functional improvement, 
are approximately 90%, for up to one 
year follow up (165-168, 170). Compli-
cations are extremely rare (165, 171), 
but because of the potential of methyl 
methacrylate leakage causing intravas-
cular embolic phenomena or compres-
sion on the spinal cord or nerve roots, 
the technique requires expertise and 
performance in a multidisciplinary envi-
ronment wherein neurosurgical support 
is available. 
Uncontrolled case series may also 
highlight a potential  for neurosurgi-
cal modalities such as cordotomy or 
rhizotomy for cancer pain relief , when 
other options have failed (172).  Other 
approaches, such as hypnosis or cog-
nitive-behavioral therapy may be help-
ful in appropriate patients (117), but 
definite evidence from adequate stud-
ies is still missing (173).
In conclusion, management of pain due 
to cancer has a potential for improve-
ment, and pertinent animal pain models 
over the last years have significantly 
advanced our current knowledge on 
the pathophysiological mechanisms 
and pharmacology of cancer pain, 
especially pain from metastatic dis-
ease to the bones. These models are 
useful tools that guide current thera-
pies and provide a testing ground for 
mechanism-based novel therapeutic 
approaches. Several very promising 
treatments, currently under considera-
tion for clinical use, have originated 
from these animal models. On the other 
hand techniques and approaches, 
such as those based on systematic 
and qualitative reviews of the literature, 
confirm efficacious treatments at the 
clinical levels. Thus, advancement of 
knowledge amongst researchers and 
clinicians may result in improvement in 
the quality of pain control and quality of 
life of cancer patients.
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